Discounted Cash Flow (DCF) Analysis Levered
MusclePharm Corporation (MSLP)
$0.0002
-0.00 (-60.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 102.16 | 88.11 | 79.67 | 64.44 | 50.04 | 41.94 | 35.14 | 29.45 | 24.68 | 20.68 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -5.13 | 1.98 | -6.52 | -0.87 | -8.04 | -2.38 | -1.99 | -1.67 | -1.40 | -1.17 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.04 | -0.13 | -0.01 | -0 | -0 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -5.17 | 1.85 | -6.54 | -0.87 | -8.04 | -2.40 | -2.01 | -1.68 | -1.41 | -1.18 |
Weighted Average Cost Of Capital
| Share price | $ 0.0,002 |
|---|---|
| Beta | -0.052 |
| Diluted Shares Outstanding | 41.17 |
| Cost of Debt | |
| Tax Rate | 0.06 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.293 |
| Total Debt | - |
| Total Equity | 0.01 |
| Total Capital | 0.01 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 102.16 | 88.11 | 79.67 | 64.44 | 50.04 | 41.94 | 35.14 | 29.45 | 24.68 | 20.68 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.13 | 1.98 | -6.52 | -0.87 | -8.04 | -2.38 | -1.99 | -1.67 | -1.40 | -1.17 |
| Capital Expenditure | -0.04 | -0.13 | -0.01 | -0 | -0 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Free Cash Flow | -5.17 | 1.85 | -6.54 | -0.87 | -8.04 | -2.40 | -2.01 | -1.68 | -1.41 | -1.18 |
| WACC | ||||||||||
| PV LFCF | -2.18 | -1.77 | -1.43 | -1.16 | -0.94 | |||||
| SUM PV LFCF | -7.98 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.29 |
| Free cash flow (t + 1) | -1.21 |
| Terminal Value | -93.53 |
| Present Value of Terminal Value | -79.55 |
Intrinsic Value
| Enterprise Value | -87.53 |
|---|---|
| Net Debt | -1.22 |
| Equity Value | -86.31 |
| Shares Outstanding | 41.17 |
| Equity Value Per Share | -2.10 |